Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
Key Financial Performance
Revenue $29.4 million, representing 3% growth over the third quarter of last year. The growth was attributed to strong treatment utilization and disciplined pricing across consoles and consumables.
Product Revenue $20.6 million, slightly ahead of $20.3 million in the prior year period. This included console sales of $8.3 million and consumable sales of $12.2 million.
Service and Other Revenue $8.9 million, a 6% increase from $8.4 million in the prior year period. Recurring revenue from the sale of Tablo consumables and service was $21.1 million, slightly ahead of the third quarter of 2024.
Non-GAAP Gross Margin 39.9%, a 350 basis point increase from last year. Excluding a 130 basis point headwind from manufacturing overhead, it would have been above 41%. Product gross margin increased to 45.7% from 43.2% in the prior year, and service and other gross margin more than doubled to 24.8% from 12.5%.
Non-GAAP Operating Expenses $22.1 million, a 17% decline compared to $26.5 million in the third quarter of 2024. This reflects the impact of actions taken to remove $80 million of annualized spend.
Non-GAAP Operating Loss $10.4 million, over 35% lower than the $16.1 million in the prior year period.
Non-GAAP Net Loss $12.4 million, 39% lower than $20.2 million in the third quarter of 2024.
Cash Usage Approximately $6 million during the quarter, driven by expanding gross margin, lower operating expenses, and inventory optimization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Tablo console sales: Increased by 8% in Q3 2025, with growing acute customer demand for in-sourcing dialysis using Tablo technology.
Clinical effectiveness: Presented data from over 1 million Tablo treatments across 750 facilities, showing rigorous treatment goals and benefits for critically ill patients.
Market opportunity: Outset Medical is expanding in large acute care markets, with nearly 1,000 acute sites using Tablo and a run rate of 1 million treatments per year.
Customer base expansion: Hundreds of customer master sales and service agreements are in place, with significant growth potential within the current customer base and new customer conversions.
Gross margin: Non-GAAP gross margin reached 39.9% in Q3 2025, with a path to 50% milestone. Product gross margin increased to 45.7%.
Expense management: Non-GAAP operating expenses declined by 17% to $22.1 million in Q3 2025, reflecting disciplined spending and a drive to profitability.
Sales leadership change: Head of Sales resigned, and sales leadership team now reports directly to the CEO. Search for a new Head of Sales is underway.
Revenue guidance revision: 2025 revenue guidance revised to $115-$120 million, down from $122-$126 million, due to timing shifts in large sales opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Process Challenges: Several large opportunities in the final stages of the sales process were delayed, shifting expected revenue from Q3 and Q4 2025 into 2026. This indicates challenges in closing deals within anticipated timelines, particularly with large health systems requiring multiple approvals.
Leadership Disruption: The resignation of the Head of Sales and the ongoing search for a replacement may cause internal disruption in Q4 2025, potentially impacting sales performance and operational stability.
Revenue Guidance Revision: 2025 revenue guidance was revised downward from $122-$126 million to $115-$120 million, reflecting slower-than-expected deal closures and other operational challenges.
Customer Ordering Patterns: Discrepancies between customer ordering patterns and actual utilization of Tablo systems have impacted recurring revenue visibility and forecasting accuracy. This issue is expected to persist into 2026.
Manufacturing Under-Absorption: A 130 basis point headwind from under-absorption of manufacturing overhead affected gross margins in Q3 2025. This issue is expected to have a diminishing but ongoing impact into 2026.
Market Execution Risks: Despite growing demand, the company faces challenges in aligning its operational execution with market opportunities, as evidenced by slower-than-expected revenue growth and deal closures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Revised 2025 revenue guidance to a range of $115 million to $120 million, down from the prior guidance of $122 million to $126 million.
Gross Margin: Expect gross margin for the full year 2025 to be in the high 30% range, with a path to reach 50% in the future.
Operating Expenses: Operating expenses for 2025 are expected to remain in the low $90 million range.
Cash Flow: Anticipate using less than $50 million in cash for 2025, a significant reduction from over $100 million used in 2024. Cash balances are expected to be sufficient through cash flow breakeven and beyond.
Sales Opportunities: Several large sales opportunities are expected to close over the fourth quarter of 2025 and into 2026, with a focus on enterprise-wide in-sourcing deals involving large health systems.
Market Demand: Hospital demand for in-sourcing dialysis with Tablo is growing, supported by clinical, operational, and financial benefits. This trend is expected to support growth for many years.
Customer Pipeline: The sales pipeline has grown significantly compared to last year, with the average size of sales opportunities increasing by more than 20%.
Treatment Revenue: Treatment revenue is expected to normalize in 2026 as ordering patterns from large acute care customers align more closely with actual utilization.
Manufacturing Efficiency: Progress is being made to optimize inventory levels and increase production, which will mitigate gross margin impacts from manufacturing under-absorption in 2026.
Market Opportunity: The company sees significant growth potential in the acute care market, with plans to expand within the current customer base and convert new customers.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What factors contributed to the quarter's performance and the change in guidance?
A:The primary driver for the shortfall was a large console opportunity slipping from Q3 into Q4. Additionally, the departure of the Head of Sales was considered a potentially disruptive situation, and the company adjusted its guidance accordingly.
Q:How did console revenues perform in the quarter, and what challenges were faced?
A:Console revenues grew compared to the third quarter of last year, but the company faced challenges in predicting the timing of deal closures. The average deal size grew by about 20%, which added complexity to forecasting.
Q:What qualities are being sought in the new sales leader, and what is the expected timeline for hiring?
A:The company is looking for a candidate with a background in capital equipment, enterprise sales, and health system standardization. The individual should be strategic, detail-oriented, and an exceptional coach. The search is already underway, but no specific timeline was provided.
Q:What is the visibility and growth outlook for the business in 2025 and beyond?
A:The company has not provided guidance beyond 2025 but remains optimistic about its long-term growth potential. The market opportunity and customer demand remain strong, but execution on deal timing needs improvement. The 2025 guidance was trimmed, and this serves as a starting point for thinking about 2026.
Q:What caused the consumables sales order timing issue, and how is it being addressed?
A:The issue was due to a limited group of higher-volume customers not placing expected orders in Q3. The company plans to work more closely with customers to understand their supply chain policies and improve forecasting. Q4 orders are expected to normalize.
Q:What impact did the Head of Sales resignation have on guidance?
A:The resignation occurred after Q3 and was factored into the revised guidance. The company anticipates potential distractions and fewer selling hours as the team adjusts to the leadership change.
Q:Are there any order cancellations or significant changes in the sales force?
A:No orders have fallen out of the pipeline, and the deals remain in the final stages of the sales process. The resignation of the Head of Sales is the primary change, and the rest of the sales team remains committed.
Q:How is the home channel performing, and what is the outlook?
A:The home channel continues to grow, with high retention rates and positive feedback from patients. The company sees growth in home programs of its largest customers and views the SNF channel as a future growth opportunity.
Q:What is the guidance philosophy for 2026, and how does it relate to 2025?
A:The company reduced its 2025 guidance by approximately $7 million, which serves as a starting point for thinking about 2026. Specific guidance for 2026 will be provided later.
Q:Is it possible for the $7 million reduction in guidance to fall into Q4?
A:The revised guidance does not assume that all deals contributing to the $7 million reduction will close in Q4. While it is not impossible, the company felt it was prudent to take a conservative approach.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026 and used vague language when discussing the potential timing of deal closures and the impact of the Head of Sales resignation. They also did not provide a clear timeline for hiring the new sales leader or detailed steps to address the consumables sales order timing issue.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AdventHealth conversion
Communications Investor
Non loss
Principal
Tablo
Technical Difficulty
approval
basis point
cash flow
cash use
charm
closing comment
consumables
detail takeaway
dozen hospital
evidence
factor
headwind
milestone
nurse
opportunity stage
order
pattern
process quarter
process result
progress path
progress sale
quarter shift
reduction cash
remainder
result opportunity
sale process
shift timing
sir
stage sale
takeaway progress
week
OM Transcript
Outset Medical, Inc. (OM) Q1 2026 Earnings Call Transcript
Unknown5-9
The earnings call presents mixed signals. Financial performance shows a revenue decline, but improved margins and reduced net loss. The next-gen Tablo launch and increased service revenue provide optimism, but cash usage and competitive pressures are concerns. The Q&A reveals confidence in future guidance, yet lacks specifics on capital order delays. Thus, the sentiment is neutral, as positives and negatives balance out.
Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript
Unknown2-11
While the company has shown improvements in operating expenses and net loss, revenue guidance has been lowered. The Q&A revealed positive sentiment towards the next-gen Tablo's potential impact but lacked specifics on ASP lift and gross margin timelines, which may cause uncertainty. The mixed signals from strong financial metrics but weak guidance, coupled with optimistic future prospects, suggest a neutral short-term stock price movement.
Outset Medical, Inc. (OM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
OM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
